PAVmed (NASDAQ:PAVM) Stock Price Down 3.3%

PAVmed Inc. (NASDAQ:PAVM)’s stock price was down 3.3% on Thursday . The stock traded as low as $7.36 and last traded at $7.43. Approximately 14,148 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 2,996,489 shares. The stock had previously closed at $7.68.

Several equities analysts have weighed in on PAVM shares. Zacks Investment Research raised PAVmed from a “sell” rating to a “hold” rating in a research note on Thursday. Maxim Group restated a “buy” rating and issued a $8.00 price target on shares of PAVmed in a report on Friday, August 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of PAVmed in a report on Friday, July 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.50.

The company has a market capitalization of $586.59 million, a P/E ratio of -12.93 and a beta of 0.31. The firm has a fifty day simple moving average of $7.68 and a 200-day simple moving average of $6.22.

PAVmed (NASDAQ:PAVM) last posted its quarterly earnings data on Thursday, August 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04). Analysts anticipate that PAVmed Inc. will post -0.48 EPS for the current year.

Several large investors have recently bought and sold shares of PAVM. Royal Bank of Canada grew its holdings in shares of PAVmed by 89.2% during the first quarter. Royal Bank of Canada now owns 5,593 shares of the company’s stock worth $25,000 after buying an additional 2,637 shares in the last quarter. FNY Investment Advisers LLC bought a new position in PAVmed in the third quarter valued at approximately $40,000. Perigon Wealth Management LLC bought a new position in PAVmed in the first quarter valued at approximately $44,000. SG Americas Securities LLC bought a new position in PAVmed in the first quarter valued at approximately $49,000. Finally, Gladstone Institutional Advisory LLC bought a new position in PAVmed in the first quarter valued at approximately $57,000. Institutional investors and hedge funds own 24.81% of the company’s stock.

About PAVmed (NASDAQ:PAVM)

PAVmed, Inc is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy, and Emerging Innovations. The GI health division comprises of EsoGuard esophageal DNA laboratory developed test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus technology.

Recommended Story: Federal Reserve

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.